2026-04-17T17:52:31Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/133262025-07-02T04:24:23Zcom_2072_378070com_2072_378040col_2072_378092

2025-07-02T04:24:23Z urn:hdl:11351/13326 Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study del Olmo-García, Maribel Hernandez-Rienda, Lorena Hernando, Jorge Custodio, Ana ANTON, BEATRIZ Gomez-Muñoz, Marta Garcia-Carbonero, Rocio Capdevila Castillon, Jaume Desnutrició Alimentació - Avaluació Pacients - Satisfacció Pàncrees - Càncer Estómac - Càncer DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasms PHENOMENA AND PROCESSES::Physiological Phenomena::Diet, Food, and Nutrition::Nutritional Physiological Phenomena::Nutritional Status HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms DISEASES::Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias gástricas FENÓMENOS Y PROCESOS::fenómenos fisiológicos::dieta, alimentación y nutrición::fenómenos fisiológicos nutricionales::estado nutricional ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas ENFERMEDADES::enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición Malnutrition; Neuroendocrine neoplasms; Sarcopenia Malnutrició; Neoplàsies neuroendocrines; Sarcopènia Malnutrición; Neoplasias neuroendocrinas; Sarcopenia Patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have impaired nutritional and physical performance due to the cancer pathophysiology and its treatment. The NUTRIGETNE study sought to characterize the nutritional status of patients with advanced GEP-NENs in Spain. This is a cross-sectional study that included patients with advanced GEP-NENs receiving active oncological treatment. Patients had a complete physical examination, anthropometry, bioelectrical impedance, dynamometry, laboratory analysis, and a comprehensive nutritional risk assessment. Malnutrition was defined according to Global Leadership Initiative on Malnutrition (GLIM) criteria. The study included 399 patients out of the 400 planned (Pearson's χ2; α 0.05). Median age was 62 years (22-83). Tumors most commonly originated in the small intestine (43.9%) and the pancreas (41.6%), 94.7% were metastatic, and 36.7%, 49.4%, and 12.5% were G1, G2, and G3, respectively. Malnutrition prevalence was 61.9% (25.8% moderate; 36.1% severe), mainly due to low muscle mass (50.9%), which was the most prevalent GLIM phenotypic criteria. Moreover, malnutrition showed a correlation with decreased hand grip strength (mean 23 vs 31.9 kg; P <.001) and phase angle (median 5o vs 5.6o; P <.001). The prevalence of sarcopenia was 15%. Malnutrition was more frequent in patients with diabetes (74.4% vs 56.7%; P <.001), NECs (82.1% vs 60.3%; P =.062), and in those treated with chemotherapy (71.2% vs 59.7%; P =.058), whereas it did not correlate with tumor origin (P =.507), histological grade (P =.781), or functionality (P =.465). Malnutrition was correlated to body mass index (BMI) (P =.015), although it was also diagnosed in a high proportion of patients with no weight loss (63%, 54.1%, and 65.1% of patients with normal BMI, overweight, and obesity, respectively). Cachexia was present in 109 (27.3%) patients. Malnutrition is very prevalent and commonly underdiagnosed in patients with GEP-NENs. It is associated with sarcopenia and a worse QoL, requiring a multifactorial nutritional assessment. Certain factors such as the presence of diabetes may require closer monitoring due to a higher risk of malnutrition. This study was funded by GETNE with the collaboration of Ipsen and Vegenat. The funders had no role in the design and conduct of the study. 2025-07-02T04:24:23Z 2025-07-02T04:24:23Z 2025-07-01T11:15:08Z 2025-07-01T11:15:08Z 2025-02 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/13326 The Oncologist;30(2) https://doi.org/10.1093/oncolo/oyae343 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess Oxford University Press Scientia